AbCellera Biologics Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss and Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2025 | 2024 | 2025 | |
| Revenue: | ||||
| Research fees | $6,289 | $8,817 | $21,516 | $19,524 |
| Licensing revenue | 218 | 138 | 767 | 10,751 |
| Milestone payments | – | – | 1,500 | – |
| Total revenue | 6,507 | 8,955 | 23,783 | 30,275 |
| Operating expenses: | ||||
| Research and development(1) | 40,969 | 55,028 | 121,183 | 136,736 |
| Sales and marketing(1) | 3,135 | 2,906 | 9,635 | 8,757 |
| General and administrative(1) | 19,147 | 22,052 | 56,691 | 57,255 |
| Depreciation, amortization, and impairment | 36,919 | 5,247 | 78,285 | 16,048 |
| Total operating expenses | 100,170 | 85,233 | 265,794 | 218,796 |
| Loss from operations | (93,663) | (76,278) | (242,011) | (188,521) |
| Other (income) expense: | ||||
| Interest income | (9,603) | (6,765) | (29,805) | (22,409) |
| Grants and incentives | (3,491) | (2,729) | (10,076) | (10,574) |
| Other | (17,937) | 1,984 | (48,564) | 2,558 |
| Total other income | (31,031) | (7,510) | (88,445) | (30,425) |
| Net loss before income tax | (62,632) | (68,768) | (153,566) | (158,096) |
| Income tax recovery | (11,525) | (11,649) | (24,919) | (20,629) |
| Net loss | $(51,107) | $(57,119) | $(128,647) | $(137,467) |
| Foreign currency translation adjustment | 841 | (41) | 488 | 1,680 |
| Comprehensive loss | $(50,266) | $(57,160) | $(128,159) | $(135,787) |
| Net loss per share | ||||
| Basic | $(0.17) | $(0.19) | $(0.44) | $(0.46) |
| Diluted | $(0.17) | $(0.19) | $(0.44) | $(0.46) |
| Weighted-average common shares outstanding | ||||
| Basic | 294,851,945 | 298,875,174 | 293,930,702 | 298,366,169 |
| Diluted | 294,851,945 | 298,875,174 | 293,930,702 | 298,366,169 |
(1)Exclusive of depreciation, amortization, and impairment
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.